Brintellix

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Vortioxetine

Available from:

H. Lundbeck A/S

ATC code:

N06AX26

INN (International Name):

vortioxetine

Therapeutic group:

Psychoanaleptics,

Therapeutic area:

Disturb depressiv, Maġġur

Therapeutic indications:

Trattament ta 'episodji depressivi maġġuri fl-adulti.

Product summary:

Revision: 23

Authorization status:

Awtorizzat

Authorization date:

2013-12-18

Patient Information leaflet

                                74
B. FULJETT TA ’TAGĦRIF
75
FULJETT TA
’
TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
BRINTELLIX 5 MG PILLOLI MIKSIJA B’RITA
Vortioxetine
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista
’
jkollok bżonn terġa
’
taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M
’
għandekx tgħaddiha lil persuni oħra. Tista
’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta
’
mard bħal tiegħek.
-
Jekk ikollok xi effetti sekondarji kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f
’
dan il-fuljett. Ara sesezzjoni 4.
F
’
DAN IL-FULJETT:
1.
X
’
inhu Brintellix u għalxiex jintuża
2.
X
’
għandek tkun taf qabel ma tieħu Brintellix
3.
Kif għandek tieħu Brintellix
4.
Effetti sekondarji possibbli
5.
Kif taħżen Brintellix
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X
’
INHU BRINTELLIX U GĦALXIEX JINTUŻA
Brintellix fih is-sustanza attiva vortioxetine. Jagħmel parti minn
grupp ta’ mediċini msejħa
antidepressanti.
Brintellix jintuża biex jikkura episodji depressivi maġġuri
f’adulti.
Brintelix intwera li jnaqqas il-firxa wiesgħa ta’ sintomi
depressivi, inkluż dwejjaq, tensjoni minn
ġewwa (tħossok ansjuż), disturbi fl-irqad (tnaqqis fl-irqad), aptit
imnaqqas, diffikultà biex
tikkonċentra, tħossok li ma inti xejn, telf ta’ interess
fl-attivitajiet favoriti, tħoss li battejt.
2.
X
’
GĦANDEK TKUN TAF QABEL MA TIEĦU BRINTELLIX
TIĦUX BRINTELLIX:
-
jekk inti allerġiku għal vortioxetine jew għal xi sustanza oħra ta
’
din il-mediċina (elenkati fis-
sezzjoni 6).
-
jekk qed tieħu mediċini oħra għad-depressjoni magħrufa bħala
inibituri mhux selettivi ta’
monoamine oxidase jew inibituri selettivi ta’ MAO-A. Staqsi
lit-tabib tiegħek jekk m’intix
ċert/a.
TWISSIJIET U PREKAWZJONIJIET
Kellem lit-tabib jew lill-ispiżja
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS 1
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Brintellix 5 mg pilloli miksija b’rita
Brintellix 10 mg pilloli miksija b’rita
Brintellix 15 mg pilloli miksija b’rita
Brintellix 20 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Brintellix 5 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha vortioxetine hydrobromide
ekwivalenti għal 5 mg vortioxetine.
Brintellix 10 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha vortioxetine hydrobromide
ekwivalenti għal 10 mg vortioxetine.
Brintellix 15 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha vortioxetine hydrobromide
ekwivalenti għal 15 mg vortioxetine.
Brintellix 20 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha vortioxetine hydrobromide
ekwivalenti għal 20 mg vortioxetine.
Għal-lista kompluta ta
’
eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola).
Brintellix 5 mg pilloli miksija b’rita
Pillola miksija b’rita ta’ lewn roża, forma ta’ lewża (5 x 8.4
mm) imnaqqxa b’
“
TL
”
fuq naħa waħda u
“
5
”
fuq in-naħa l-oħra.
Brintellix 10 mg pilloli miksija b’rita
Pillola miksija b’rita ta’ lewn isfar, forma ta’ lewża (5 x 8.4
mm) imnaqqxa b’
“
TL” fuq naħa waħda u
“
10” fuq in-naħa l-oħra.
Brintellix 15 mg pilloli miksija b’rita
Pillola miksija b’rita ta’ lewn oranġjo, forma ta’ lewża (5 x
8.4 mm) imnaqqxa b’
“
TL” fuq naħa waħda
u
“
15” fuq in-naħa l-oħra.
Brintellix 20 mg pilloli miksija b’rita
Pillola miksija b’rita ta’ lewn aħmar, forma ta’ lewża (5 x
8.4 mm) imnaqqxa b’
“
TL” fuq naħa waħda
u
“
20
”
fuq in-naħa l-oħra.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Brintellix huwa indikat għall-kura ta’ episodji depressivi
maġġuri fl-adulti.
3
4.2
POŻOLOĠIJA U METODU TA
’
KIF GĦANDU JINGĦATA
Pożoloġija
Id-doża tal-bidu u dik irrakkomandata ta’ Brintellix hija ta’ 10
mg vortioxetine darba k
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-01-2024
Public Assessment Report Public Assessment Report Bulgarian 14-01-2014
Patient Information leaflet Patient Information leaflet Spanish 16-01-2024
Public Assessment Report Public Assessment Report Spanish 14-01-2014
Patient Information leaflet Patient Information leaflet Czech 16-01-2024
Public Assessment Report Public Assessment Report Czech 14-01-2014
Patient Information leaflet Patient Information leaflet Danish 16-01-2024
Public Assessment Report Public Assessment Report Danish 14-01-2014
Patient Information leaflet Patient Information leaflet German 16-01-2024
Public Assessment Report Public Assessment Report German 14-01-2014
Patient Information leaflet Patient Information leaflet Estonian 16-01-2024
Public Assessment Report Public Assessment Report Estonian 14-01-2014
Patient Information leaflet Patient Information leaflet Greek 16-01-2024
Public Assessment Report Public Assessment Report Greek 14-01-2014
Patient Information leaflet Patient Information leaflet English 16-01-2024
Public Assessment Report Public Assessment Report English 14-01-2014
Patient Information leaflet Patient Information leaflet French 16-01-2024
Public Assessment Report Public Assessment Report French 14-01-2014
Patient Information leaflet Patient Information leaflet Italian 16-01-2024
Public Assessment Report Public Assessment Report Italian 14-01-2014
Patient Information leaflet Patient Information leaflet Latvian 16-01-2024
Public Assessment Report Public Assessment Report Latvian 14-01-2014
Patient Information leaflet Patient Information leaflet Lithuanian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-01-2024
Public Assessment Report Public Assessment Report Lithuanian 14-01-2014
Patient Information leaflet Patient Information leaflet Hungarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 16-01-2024
Public Assessment Report Public Assessment Report Hungarian 14-01-2014
Patient Information leaflet Patient Information leaflet Dutch 16-01-2024
Public Assessment Report Public Assessment Report Dutch 14-01-2014
Patient Information leaflet Patient Information leaflet Polish 16-01-2024
Public Assessment Report Public Assessment Report Polish 14-01-2014
Patient Information leaflet Patient Information leaflet Portuguese 16-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 16-01-2024
Public Assessment Report Public Assessment Report Portuguese 14-01-2014
Patient Information leaflet Patient Information leaflet Romanian 16-01-2024
Public Assessment Report Public Assessment Report Romanian 14-01-2014
Patient Information leaflet Patient Information leaflet Slovak 16-01-2024
Public Assessment Report Public Assessment Report Slovak 14-01-2014
Patient Information leaflet Patient Information leaflet Slovenian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 16-01-2024
Public Assessment Report Public Assessment Report Slovenian 14-01-2014
Patient Information leaflet Patient Information leaflet Finnish 16-01-2024
Public Assessment Report Public Assessment Report Finnish 14-01-2014
Patient Information leaflet Patient Information leaflet Swedish 16-01-2024
Public Assessment Report Public Assessment Report Swedish 14-01-2014
Patient Information leaflet Patient Information leaflet Norwegian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 16-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 16-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 16-01-2024
Patient Information leaflet Patient Information leaflet Croatian 16-01-2024
Public Assessment Report Public Assessment Report Croatian 14-01-2014

Search alerts related to this product

View documents history